Private Market View

JamJam Therapeutics

Seoul, South Korea · Founded 2023 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$650K
Last round

Key facts

  • It has raised $650K; the latest was Accelerator/Incubator in Jun 2025.
  • Notable investors include Tech Incubator Program for Startup, Smilegate Investment, Korea Investment Accelerator, COMEUP STARS, Digital Healthcare Partners10 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 10 names
  • ·Watchlist + deal alerts for JamJam Therapeutics
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for JamJam Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About JamJam Therapeutics

Developer of a rehabilitation software designed for children with slow development. The company's game is designed so that disabled children can enjoy rehabilitation exercises at home without any special equipment, enabling users to experience the effects of the game and reduce the burden of rehabilitation.

Sector
Healthcare
HQ
Seoul, South Korea
Founded
2023
Employees
14
Ownership
Privately Held (backing)
PA Mark — not yet priced

JamJam Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in JamJam Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on JamJam Therapeutics in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.